Articles On Cardiex (ASX:CDX)

Cardiex has announced a $3.25m placement to scale product rollouts and drive growth in its clinical trials business in 2025 FDA-cleared Pulse medical device has attracted 20,000+ waitlist members Pre-order sales already underway in the US...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

Stocks surge and US dollar jumps as Trump leads ASX rises  amid tight US election race Bitcoin hits record as Trump-linked trades soar   Stocks surged, Treasury yields soared, and the US dollar looked set for its biggest gain since March...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Cardiex opens US pre-orders for the CONNEQT Pulse, targeting consumer arterial health monitoring Over 20,000 sign-ups on the waitlist as Cardiex rolls out exclusive pre-order invitations Phased launch aims to streamline customer experience...

CardieX wins US$525,000 National Institutes of Health award for innovation in treatment of hypertensive disorders in pregnancy Medtech’s Pulse device is set to launch in November, expanding access to advanced arterial health monitoring The...

  ASX falls as tech sector drops on Euro chipmaker ASML’s report Gold prices near record highs with Evolution Mining rising Trump defends tariffs and Fed influence in recent interview   The ASX fell 0.41%, led by declines in the Tech sec...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Cardiex shares climb 15% on news the company is set to surpass its FY24 revenue projections Company is on track to double FY23 revenue amid a pipeline of new products and strategic partnerships The company has also announced its first glob...

ASX rose  as the RBA held interest rates at 12-year high 4.35pc All 11 sectors on the ASX gained, with significant moves from Pilbara and Fortescue  ASX to launch first bitcoin-linked ETF on Thursday   Aussie stocks bounced back by +0.8%...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets are lucky to close a smidgen higher IT and Healthcare sectors offset a 2pc loss for Energy Small Caps led by Enova Mining   Australian sharemarkets lacked all the vim, vigour and vinegar one associates with victory on Mond...

Recce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the ASX!   Recce to expand diabetes foot ulcer Phase 1/2 trial An independent Safety Committee h...

Stockhead’s Top 10 at 10, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

14 million raise for CardieX consisted of a placement, shareholder entitlement offer, and a funding commitment agreement. Placement was cornerstoned by Regal Funds Management. C2 Ventures, the investment vehicle of the company’s CEO and ch...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Benchmark index settles almost -0.6% lower on Tuesday All sectors bar Healthcare and Financials in the red Small caps led by NickelSearch and Biotron A positive lead from Wall Street overnight didn’t sell well on local markets, which were...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

  ASX 200 find 0.5% to start the week, LTR looks ready to sell Energy stocks and miners offset IT and Consumer Discretionary losses Small cap winners led by EMD and GLH   Local markets were led higher on Monday, supported by resource busi...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

ASX 200 closes about 0.06% in the green (so, really, we ended in the chartreuse) down -1.2 in August Telco and IT Sectors offset Staples and Energy losses Small cap winners include 29M, CDX and HLA   Volatility, uncertainty and indecisio...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Medical devices offer faster route to commercialisation than drugs How newly listed Curvebeam AI aims to grab market share Stockhead reached out to Curvebeam AI CEO, Greg Brown   Despite the recent rally, the ASX Healthcare Index (XHJ) is...

Stroke has long been recognised as being among Australia’s most costly disease groups.  It occurs when a blood vessel supplying blood to the brain either suddenly becomes blocked or ruptures and begins to bleed which can result in part of t...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

The S&P ASX 200 was down 2.5% in May, with mid caps performing the best and small caps lagging blue chips The S&P ASX 200 Information Technology sector performed the best in May, up 11.6% following strong AI interest Wildcat Resou...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

The benchmark kicked off well at +0.8% before deflating to finish on +0.4% Utilities (+1.21%)win the day, while InfoTech (-1.20%) takes a body blow. Lincoln Minerals (ASX:LML) tops the charts, up 36% for absolutely no reason at all.   Loc...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Equities research shop MST Access has upgraded its valuation on CardieX after the leading cardiovascular medtech’s world’s first, customizable vascular biometric monitor received regulatory clearance to provide medical grade arterial heart...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The world’s first, customisable vascular biometric monitor has received regulatory clearance to provide medical grade arterial heart health metrics to patients and clinicians. The CONNEQT Pulse arterial health monitor, has received 510(K) c...

CardieX jumps 16pc after getting FDA clearance for CONNEQT Pulse CONNEQT Pulse is a world first multi-use vascular biometric monitor  Three ASX biotechs received clearance to commence studies   Health devices and wearables tech company Ca...

ASX 200 benchmark closes 0.11% lower after a fickle day on the bourse Iron ore price drops to five month lows, making (almost) everyone sad Larvotto ends up on top of the Small Caps, adding 61.9% for the day   Aussie markets were a tad me...